Datos y Bibliografía
-
Bibliografía
(Bibliografía general con utilidad en distintos grupos de fármacos)
Shepherd R, Harrap KR. Modulation of the toxicity and antitumour activity of alkylating drugs by steroids. Br J Cancer. 1982 Mar;45(3):413-20. doi: 10.1038/bjc.1982.69. PMID: 7073935; PMCID: PMC2010934.
Kintzel PE. Anticancer drug-induced kidney disorders. Drug Saf. 2001 Jan;24(1):19-38. doi: 10.2165/00002018-200124010-00003. PMID: 11219485.
Coiffier B, Altman A, Pui CH, Younes A, Cairo MS. Guidelines for the management of pediatric and adult tumor lysis syndrome: an evidence-based review. J Clin Oncol. 2008 Jun 1;26(16):2767-78. doi: 10.1200/JCO.2007.15.0177. Erratum in: J Clin Oncol. 2010 Feb 1;28(4):708. PMID: 18509186.
Seiter K. Toxicity of the topoisomerase I inhibitors. Expert Opin Drug Saf. 2005 Jan;4(1):45-53. doi: 10.1517/14740338.4.1.45. PMID: 15709897.
Cairo MS, Coiffier B, Reiter A, Younes A; TLS Expert Panel. Recommendations for the evaluation of risk and prophylaxis of tumour lysis syndrome (TLS) in adults and children with malignant diseases: an expert TLS panel consensus. Br J Haematol. 2010 May;149(4):578-86. doi: 10.1111/j.1365-2141.2010.08143.x. Epub 2010 Mar 16. PMID: 20331465.
Emergent toxicities associated with the use of mTOR inhibitors in patients with advanced renal carcinoma. Rodriguez-Pascual J, Cheng E, Maroto P, Duran I.Anticancer Drugs. 2010 Jun;21(5):478-86. doi: 10.1097/cad.0b013e32833760bf.PMID: 20401967
Massard C, Patard JJ, Hermine O, Ravaud A. Gestion des effets secondaires des thérapies ciblées dans le cancer du rein: effets secondaires iatrogéniques [Management of side effects of targeted therapies in renal cancer: iatrogenic side effects]. Bull Cancer. 2011;98(3 Suppl):S79-94. French. doi: 10.1684/bdc.2011.1447. PMID: 25819130.
Vello Román A, Samprón Rodríguez M, Pazos Arias B, Romero Reinoso C, Peteiro Cancelo A. Nefropatía tras la administración de inhibidores de la angiogénesis [Nephropathy following administration of angiogenesis inhibitors]. Nefrologia. 2011;31(2):221-2. Spanish. doi: 10.3265/Nefrologia.pre2010.Nov.10729. PMID: 21461019.
Wendorff TJ, Schmidt BH, Heslop P, Austin CA, Berger JM. The structure of DNA-bound human topoisomerase II alpha: conformational mechanisms for coordinating inter-subunit interactions with DNA cleavage. J Mol Biol. 2012 Dec 7;424(3-4):109-24. doi: 10.1016/j.jmb.2012.07.014. Epub 2012 Jul 25. PMID: 22841979; PMCID: PMC3584591.
Pardoll DM. The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer. 2012 Mar 22;12(4):252-64. doi: 10.1038/nrc3239. PMID: 22437870; PMCID: PMC4856023.
Dy GK, Adjei AA. Understanding, recognizing, and managing toxicities of targeted anticancer therapies. CA Cancer J Clin. 2013 Jul-Aug;63(4):249-79. doi: 10.3322/caac.21184. Epub 2013 May 28. PMID: 23716430.
Airy M, Raghavan R, Truong LD, Eknoyan G. Tubulointerstitial nephritis and cancer chemotherapy: update on a neglected clinical entity. Nephrol Dial Transplant. 2013 Oct;28(10):2502-9. doi: 10.1093/ndt/gft241. Epub 2013 Sep 5. PMID: 24009289.
Chen DS, Mellman I. Oncology meets immunology: the cancer-immunity cycle. Immunity. 2013 Jul 25;39(1):1-10. doi: 10.1016/j.immuni.2013.07.012. PMID: 23890059
Jhaveri KD, Fishbane S. Nephrology Crossword: Onco-nephrology--chemotherapy agents and nephrotoxicity. Kidney Int. 2013 Aug;84(2):421-2. doi: 10.1038/ki.2013.50. PMID: 23903433.
Glomerular diseases associated with cancer, chemotherapy,and hematopoietic stem cell transplantation. Jhaveri KD, Shah HH, Patel C, Kadiyala A, Stokes MB, Radhakrishnan J.Adv Chronic Kidney Dis. 2014 Jan;21(1):48-55. doi: 10.1053/j.ackd.2013.08.003.PMID: 24359986
Wang Q, Qi Y, Zhang D, Gong C, Yao A, Xiao Y, Yang J, Zhou F, Zhou Y. Electrolyte disorders assessment in solid tumor patients treated with anti-EGFR monoclonal antibodies: a pooled analysis of 25 randomized clinical trials. Tumour Biol. 2015 May;36(5):3471-82. doi: 10.1007/s13277-014-2983-9. Epub 2014 Dec 28. PMID: 25542231; PMCID: PMC4445483.
Drug-induced glomerular disease: direct cellular injury. Markowitz GS, Bomback AS, Perazella MA.Clin J Am Soc Nephrol. 2015 Jul 7;10(7):1291-9. doi: 10.2215/CJN.00860115. Epub 2015 Apr 10.PMID: 25862776
Clinicopathological features of acute kidney injury associated with immune checkpoint inhibitors. Cortazar FB, Marrone KA, Troxell ML, Ralto KM, Hoenig MP, Brahmer JR, Le DT, Lipson EJ, Glezerman IG, Wolchok J, Cornell LD, Feldman P, Stokes MB, Zapata SA, Hodi FS, Ott PA, Yamashita M, Leaf DE.Kidney Int. 2016 Sep;90(3):638-47. doi: 10.1016/j.kint.2016.04.008. Epub 2016 Jun 7.PMID: 27282937
Liamis G. Electrolyte disorders associated with the use of anticancer drugs. Eur J Pharmacol. 2016. PMID: 26939882.
Jhaveri KD. Renal effects of novel anticancer targeted therapies: a review of the Food and Drug Administration Adverse Event Reporting System. Kidney Int. 2016
Jhaveri KD. Adverse Renal Effects of Novel Molecular Oncologic Targeted Therapies: A Narrative Review. KI Rep. 2016. PMID: 29318210; PMCID: PMC5720524.
Linardou H, Gogas H. Toxicity management of immunotherapy for patients with metastatic melanoma. Ann Transl Med. 2016 Jul;4(14):272. doi: 10.21037/atm.2016.07.10. PMID: 27563659; PMCID: PMC4971373.
Belliere J, Meyer N, Mazieres J, Ollier S, Boulinguez S, Delas A, Ribes D, Faguer S. Acute interstitial nephritis related to immune checkpoint inhibitors. Br J Cancer. 2016 Dec 6;115(12):1457-1461. doi: 10.1038/bjc.2016.358. Epub 2016 Nov 10. PMID: 27832664; PMCID: PMC5155358.
Izzedine H, El-Fekih RK, Perazella MA. The renal effects of ALK inhibitors. Invest New Drugs. 2016 Oct;34(5):643-9. doi: 10.1007/s10637-016-0379-y. Epub 2016 Jul 29. PMID: 27468827.
Adverse Renal Effects of Immune Checkpoint Inhibitors: A Narrative Review. Wanchoo R, Karam S, Uppal NN, Barta VS, Deray G, Devoe C, Launay-Vacher V, Jhaveri KD; Cancer and Kidney International Network Workgroup on Immune Checkpoint Inhibitors.Am J Nephrol. 2017;45(2):160-169. doi: 10.1159/000455014. Epub 2017 Jan 12.PMID: 28076863
Moledina DG, Perazella MA. Drug-Induced Acute Interstitial Nephritis. Clin J Am Soc Nephrol. 2017 Dec 7;12(12):2046-2049. doi: 10.2215/CJN.07630717. Epub 2017 Sep 11. PMID: 28893923; PMCID: PMC5718279.
Sleilalty G, El Rassy E, Assi T, Al Rassy N, Nasseh J, Rizkallah J, Finianos S, Azar H, Chelala DN, El Karak F, Kattan J, Ghosn M. Evaluation of chronic kidney disease in cancer patients: is there a preferred estimation formula? Intern Med J. 2018 Nov;48(11):1382-1388. doi: 10.1111/imj.13933. Erratum in: Intern Med J. 2019 Oct;49(10):1341. doi: 10.1111/imj.14643. PMID: 29660234.
Zhang H, Feng Q, Chen WD, Wang YD. HGF/c-MET: A Promising Therapeutic Target in the Digestive System Cancers. Int J Mol Sci. 2018 Oct 23;19(11):3295. doi: 10.3390/ijms19113295. PMID: 30360560; PMCID: PMC6274736.
Wanchoo R, Abudayyeh A, Doshi M, Edeani A, Glezerman IG, Monga D, Rosner M, Jhaveri KD. Renal Toxicities of Novel Agents Used for Treatment of Multiple Myeloma. Clin J Am Soc Nephrol. 2017 Jan 6;12(1):176-189. doi: 10.2215/CJN.06100616. Epub 2016 Sep 21. PMID: 27654928; PMCID: PMC5220662.
El Bitar S, Weerasinghe C, El-Charabaty E, Odaimi M. Renal Tubular Acidosis an Adverse Effect of PD-1 Inhibitor Immunotherapy. Case Rep Oncol Med. 2018 Jan 31;2018:8408015. doi: 10.1155/2018/8408015. PMID: 29666732; PMCID: PMC5831873.
Jhaveri KD, Rosner MH. Chimeric antigen receptor T cell therapy and the kidney: what the nephrologist needs to know. Clin J Am Soc Nephrol 2018;13(5):796–8
Uppal NN, Monga D, Vernace MA, Mehtabdin K, Shah HH, Bijol V, Jhaveri KD. Kidney diseases associated with Waldenström macroglobulinemia. Nephrol Dial Transplant. 2019 Oct 1;34(10):1644-1652. doi: 10.1093/ndt/gfy320. PMID: 30380110.
Kidney Complications of Immune Checkpoint Inhibitors: A Review. Shingarev R, Glezerman IG.Am J Kidney Dis. 2019 Oct;74(4):529-537. doi: 10.1053/j.ajkd.2019.03.433. Epub 2019 Jul 11.PMID: 31303350
de Francisco ALM, Macía M, Alonso F, García P, Gutierrez E, Quintana LF, Quiroga B, Torregrosa I. Onco-Nephrology: Cancer, chemotherapy and kidney. Nefrologia (Engl Ed). 2019 Sep-Oct;39(5):473-481. English, Spanish. doi: 10.1016/j.nefro.2018.10.016. Epub 2019 Mar 29. PMID: 30929891.
Renal Vasculitis and Pauciimmune Glomerulonephritis Associated With Immune Checkpoint Inhibitors.Gallan AJ, Alexander E, Reid P, Kutuby F, Chang A, Henriksen KJ.Am J Kidney Dis. 2019 Dec;74(6):853-856. doi: 10.1053/j.ajkd.2019.04.016. Epub 2019 Jun 14.PMID: 31204194
Moliz C, Cavero T, Morales E, Gutiérrez E, Alonso M, Praga M. Renal damage secondary to check-point inhibitors. Nefrologia (Engl Ed). 2020 Mar- Apr;40(2):206-208. English, Spanish. doi: 10.1016/j.nefro.2019.05.004. Epub 2019 Oct 12. PMID: 31615688.
Kitchlu A, McArthur E, Amir E, et al. Acute kidney injury in patients receiving systemic treatment for cancer: a populationbased cohort study. J Natl Cancer Inst. 2019;111(7):727-736. https://doi.org/1 0.1093/jnci/djy167
Charmetant X, Teuma C, Lake J, Dijoud F, Frochot V, Deeb A. A new expression of immune checkpoint inhibitors' renal toxicity: when distal tubular acidosis precedes creatinine elevation. Clin Kidney J. 2019 May 14;13(1):42-45. doi: 10.1093/ckj/sfz051. PMID: 32082551; PMCID: PMC7025331.
Zibetti Dal Molin G, Westin SN, Msaouel P, Gomes LM, Dickens A, Coleman RL. Discrepancy in calculated and measured glomerular filtration rates in patients treated with PARP inhibitors. Int J Gynecol Cancer. 2020 Jan;30(1):89-93. doi: 10.1136/ijgc-2019-000714. Epub 2019 Dec 1. PMID: 31792084.
Dixon BN, Daley RJ, Buie LW, Hsu M, Park JH, Brentjens RJ, et al. Correlation of IL-6 secretion and hyponatremia with the use of CD19+ chimeric antigen receptor T-cells. Clin Nephrol 2020;93(1):42–6
Acute interstitial nephritis associated with immune checkpoint inhibitors: a single-centre experience. Oleas D, Bolufer M, Agraz I, Felip E, Muñoz E, Gabaldón A, Bury R, Espinel E, Serón D, García-Carro C, Soler MJ.Clin Kidney J. 2020 Feb 10;14(5):1364-1370. doi: 10.1093/ckj/sfaa008. eCollection 2021 May.PMID: 34221369
Kitchlu A, Jhaveri KD, Wadhwani S, Deshpande P, Harel Z, Kishibe T, Henriksen K, Wanchoo R. A Systematic Review of Immune Checkpoint Inhibitor-Associated Glomerular Disease. Kidney Int Rep. 2020 Oct 16;6(1):66-77. doi: 10.1016/j.ekir.2020.10.002. PMID: 33426386; PMCID: PMC7783581.
Verzicco I, Regolisti G, Quaini F, Bocchi P, Brusasco I, Ferrari M, Passeri G, Cannone V, Coghi P, Fiaccadori E, Vignali A, Volpi R, Cabassi A. Electrolyte Disorders Induced by Antineoplastic Drugs. Front Oncol. 2020 May 19;10:779. doi: 10.3389/fonc.2020.00779. PMID: 32509580; PMCID: PMC7248368.
Kitchlu A, Jhaveri KD, Wadhwani S, Deshpande P, Harel Z, Kishibe T, Henriksen K, Wanchoo R. A Systematic Review of Immune Checkpoint Inhibitor-Associated Glomerular Disease. Kidney Int Rep. 2020 Oct 16;6(1):66-77. doi: 10.1016/j.ekir.2020.10.002. PMID: 33426386; PMCID: PMC7783581.
Herrmann SM, Alexander MP, Romero MF, Zand L. Renal Tubular Acidosis and Immune Checkpoint Inhibitor Therapy: An Immune-Related Adverse Event of PD-1 Inhibitor-A Report of 3 Cases. Kidney Med. 2020 Aug 11;2(5):657-662. doi: 10.1016/j.xkme.2020.05.015. PMID: 33089143; PMCID: PMC7568062.
Sprangers B, Abudayyeh A, Latcha S, Perazella MA, Jhaveri KD. How to determine kidney function in cancer patients? Eur J Cancer. 2020 Jun;132:141-149. doi: 10.1016/j.ejca.2020.03.026. Epub 2020 Apr 30. PMID: 32361629.
The Mechanism of Drug Nephrotoxicity and the Methods for Preventing Kidney Damage. Kwiatkowska E, Domański L, Dziedziejko V, Kajdy A, Stefańska K, Kwiatkowski S.Int J Mol Sci. 2021 Jun 6;22(11):6109. doi: 10.3390/ijms22116109.PMID: 34204029
Kitchlu A, Jhaveri KD, Sprangers B, Yanagita M, Wanchoo R. Immune checkpoint inhibitor use in patients with end-stage kidney disease: an analysis of reported cases and literature review. Clin Kidney J. 2021 May 8;14(9):2012-2022. doi: 10.1093/ckj/sfab090. PMID: 34476087; PMCID: PMC8406068.
Workeneh BT, Jhaveri KD, Rondon-Berrios H. Hyponatremia in the cancer patient. Kidney Int. 2020 Oct;98(4):870-882. doi: 10.1016/j.kint.2020.05.015. Epub 2020 Jun 1. PMID: 32497528.
Martínez-Jiménez F, Muiños F, Sentís I, Deu-Pons J, Reyes-Salazar I, Arnedo- Pac C, Mularoni L, Pich O, Bonet J, Kranas H, Gonzalez-Perez A, Lopez-Bigas N. A compendium of mutational cancer driver genes. Nat Rev Cancer. 2020 Oct;20(10):555-572. doi: 10.1038/s41568-020-0290-x. Epub 2020 Aug 10. PMID: 32778778.
Porta C, Bamias A, Danesh FR, Dębska-Ślizień A, Gallieni M, Gertz MA, Kielstein JT, Tesarova P, Wong G, Cheung M, Wheeler DC, Winkelmayer WC, Małyszko J; Conference Participants. KDIGO Controversies Conference on onco-nephrology: understanding kidney impairment and solid-organ malignancies, and managing kidney cancer. Kidney Int. 2020 Nov;98(5):1108-1119. doi: 10.1016/j.kint.2020.06.046. PMID: 33126977.
AJKD 2020. GELFAND Gelfand. TTº renal de soporte en cáncer. Core curriculum 2020.
Gudsoorkar P, Sise ME, Jhaveri KD. Onconephrology: The Growth of Cancer- Kidney Connection. Adv Chronic Kidney Dis. 2021 Sep;28(5):391-393. doi: 10.1053/j.ackd.2021.12.003. PMID: 35190105.
Gudsoorkar P, Langote A, Vaidya P, Meraz-Muñoz AY. Acute Kidney Injury in Patients With Cancer: A Review of Onconephrology. Adv Chronic Kidney Dis. 2021 Sep;28(5):394-401.e1. doi: 10.1053/j.ackd.2021.09.008. PMID: 35190106.
Gupta S, Portales-Castillo I, Daher A, Kitchlu A. Conventional Chemotherapy Nephrotoxicity. Adv Chronic Kidney Dis. 2021 Sep;28(5):402-414.e1. doi: 10.1053/j.ackd.2021.08.001. PMID: 35190107.
Kala J, Salman LA, Geara AS, Izzedine H. Nephrotoxicity From Molecularly Targeted Chemotherapeutic Agents. Adv Chronic Kidney Dis. 2021 Sep;28(5):415-428.e1. doi: 10.1053/j.ackd.2021.09.003. PMID: 35190108.
Kala J, Finkel KW. Onconephrology. Crit Care Clin. 2021 Apr;37(2):365-384. doi: 10.1016/j.ccc.2020.11.004. Epub 2021 Feb 13. PMID: 33752861.
Pelletier K, Škrtić M, Kitchlu A. Cancer therapy-induced hyponatremia: A case-illustrated reviewJ Oncol-Nephrol 2021;5(1):70-78.
Van Wynsberghe, M.; Flejeo, J.; Sakhi, H.; Ollero, M.; Sahali, D.; Izzedine, H.; Henique, C. Nephrotoxicity of Anti-Angiogenic Therapies. Diagnostics 2021, 11, 640.
Manohar S, Jhaveri KD, Perazella MA. Immunotherapy-Related Acute Kidney Injury. Adv Chronic Kidney Dis. 2021 Sep;28(5):429-437.e1. doi: 10.1053/j.ackd.2021.07.006. PMID: 35190109.
Barbar T, Jaffer Sathick I. Tumor Lysis Syndrome. Adv Chronic Kidney Dis. 2021 Sep;28(5):438-446.e1. doi: 10.1053/j.ackd.2021.09.007. PMID: 35190110.
Murakami N, Mulvaney P, Danesh M, Abudayyeh A, Diab A, Abdel-Wahab N, Abdelrahim M, Khairallah P, Shirazian S, Kukla A, Owoyemi IO, Alhamad T, Husami S, Menon M, Santeusanio A, Blosser CD, Zuniga SC, Soler MJ, Moreso F, Mithani Z, Ortiz-Melo D, Jaimes EA, Gutgarts V, Lum E, Danovitch GM, Cardarelli F, Drews RE, Bassil C, Swank JL, Westphal S, Mannon RB, Shirai K, Kitchlu A, Ong S, Machado SM, Mothi SS, Ott PA, Rahma O, Hodi FS, Sise ME, Gupta S, Leaf DE, Devoe CE, Wanchoo R, Nair VV, Schmults CD, Hanna GJ, Sprangers B, Riella LV, Jhaveri KD; Immune Checkpoint Inhibitors in Solid Organ Transplant Consortium. A multi- center study on safety and efficacy of immune checkpoint inhibitors in cancer patients with kidney transplant. Kidney Int. 2021 Jul;100(1):196-205. doi: 10.1016/j.kint.2020.12.015. Epub 2020 Dec 24. PMID: 33359528; PMCID: PMC8222056.
Braet P, Sartò GVR, Pirovano M, Sprangers B, Cosmai L. Treatment of acute kidney injury in cancer patients. Clin Kidney J. 2021 Dec 24;15(5):873-884. doi: 10.1093/ckj/sfab292. PMID: 35498895; PMCID: PMC9050558.
Brahmer JR, Abu-Sbeih H, Ascierto PA, Brufsky J, Cappelli LC, Cortazar FB, Gerber DE, Hamad L, Hansen E, Johnson DB, Lacouture ME, Masters GA, Naidoo J, Nanni M, Perales MA, Puzanov I, Santomasso BD, Shanbhag SP, Sharma R, Skondra D, Sosman JA, Turner M, Ernstoff MS. Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immune checkpoint inhibitor-related adverse events. J Immunother Cancer. 2021 Jun;9(6):e002435. doi: 10.1136/jitc-2021-002435. PMID: 34172516; PMCID: PMC8237720.
Cancers (Basel). 2021. Kommalapati A. FGFR Inhibitors in Oncology: Insight on the Management of Toxicities in Clinical Practice.
Rosner MH, DeMauro Renaghan A. Disorders of Divalent Ions (Magnesium, Calcium, and Phosphorous) in Patients With Cancer. Adv Chronic Kidney Dis. 2021 Sep;28(5):447-459.e1. doi: 10.1053/j.ackd.2021.09.005. PMID: 35190111.
Saly DL, Eswarappa MS, Street SE, Deshpande P. Renal Cell Cancer and Chronic Kidney Disease. Adv Chronic Kidney Dis. 2021 Sep;28(5):460-468.e1. doi: 10.1053/j.ackd.2021.10.008. PMID: 35190112.
Lee M, Wang Q, Wanchoo R, Eswarappa M, Deshpande P, Sise ME. Chronic Kidney Disease in Cancer Survivors. Adv Chronic Kidney Dis. 2021 Sep;28(5):469-476.e1. doi: 10.1053/j.ackd.2021.10.007. PMID: 35190113.
Valério P, Barreto JP, Ferreira H, Chuva T, Paiva A, Costa JM. Thrombotic microangiopathy in oncology - a review. Transl Oncol. 2021 Jul;14(7):101081. doi: 10.1016/j.tranon.2021.101081. Epub 2021 Apr 13. PMID: 33862523; PMCID: PMC8065296.
Gudsoorkar P, Ruf R, Adnani H, Safdar K, Sparks MA. Onco-hypertension: An Emerging Specialty. Adv Chronic Kidney Dis. 2021 Sep;28(5):477-489.e1. doi: 10.1053/j.ackd.2021.09.011. PMID: 35190114.
Stotter BR, Chan C, Chanchlani R. Late Kidney Effects of Childhood Cancer and Cancer Therapies. Adv Chronic Kidney Dis. 2021 Sep;28(5):490-501.e1. doi: 10.1053/j.ackd.2021.09.001. PMID: 35190115.
Shirazian S, Starakiewicz P, Latcha S. Cancer Screening in End-Stage Kidney Disease. Adv Chronic Kidney Dis. 2021 Sep;28(5):502-508.e1. doi: 10.1053/j.ackd.2021.09.006. PMID: 35190116.
Isik B, Alexander MP, Manohar S, Vaughan L, Kottschade L, Markovic S, Lieske J, Kukla A, Leung N, Herrmann SM. Biomarkers, Clinical Features, and Rechallenge for Immune Checkpoint Inhibitor Renal Immune-Related Adverse Events. Kidney Int Rep. 2021 Feb 2;6(4):1022-1031. doi: 10.1016/j.ekir.2021.01.013. PMID: 33912752; PMCID: PMC8071627.
Chanson N, Ramos-Casals M, Pundole X, Suijkerbuijk K, José de Barros E Silva M, Lidar M, Benesova K, Leipe J, Acar-Denizli N, Pradère P, Michot JM, Voisin AL, Suárez-Almazor ME, Radstake TRD, Fernandes Moça Trevisani V, Schulze-Koops H, Melin A, Robert C, Mariette X, Baughman RP, Lambotte O; ICIR; Coordination; Co-Convenors; Steering Committee; Research Fellows; Data Scientist. Immune checkpoint inhibitor-associated sarcoidosis: A usually benign disease that does not require immunotherapy discontinuation. Eur J Cancer. 2021 Nov;158:208-216. doi: 10.1016/j.ejca.2021.05.041. Epub 2021 Aug 25. PMID: 34452793.
Zhong L, Li Y, Xiong L, Wang W, Wu M, Yuan T, Yang W, Tian C, Miao Z, Wang T, Yang S. Small molecules in targeted cancer therapy: advances, challenges, and future perspectives. Signal Transduct Target Ther. 2021 May 31;6(1):201. doi: 10.1038/s41392-021-00572-w. PMID: 34054126; PMCID: PMC8165101
Gupta S, Short SAP, Sise ME, Prosek JM, Madhavan SM, Soler MJ, Ostermann M, Herrmann SM, Abudayyeh A, Anand S, Glezerman I, Motwani SS, Murakami N, Wanchoo R, Ortiz-Melo DI, Rashidi A, Sprangers B, Aggarwal V, Malik AB, Loew S, Carlos CA, Chang WT, Beckerman P, Mithani Z, Shah CV, Renaghan AD, Seigneux S, Campedel L, Kitchlu A, Shin DS, Rangarajan S, Deshpande P, Coppock G, Eijgelsheim M, Seethapathy H, Lee MD, Strohbehn IA, Owen DH, Husain M, Garcia-Carro C, Bermejo S, Lumlertgul N, Seylanova N, Flanders L, Isik B, Mamlouk O, Lin JS, Garcia P, Kaghazchi A, Khanin Y, Kansal SK, Wauters E, Chandra S, Schmidt-Ott KM, Hsu RK, Tio MC, Sarvode Mothi S, Singh H, Schrag D, Jhaveri KD, Reynolds KL, Cortazar FB, Leaf DE; ICPi-AKI Consortium Investigators. Acute kidney injury in patients treated with immune checkpoint inhibitors. J Immunother Cancer. 2021 Oct;9(10):e003467. doi: 10.1136/jitc-2021-003467. Erratum in: J Immunother Cancer. 2023 Apr;11(4):e003467corr1. doi: 10.1136/jitc-2021-003467corr1. PMID: 34625513; PMCID: PMC8496384.
Rosner MH, Jhaveri KD, McMahon BA, Perazella MA. Onconephrology: The intersections between the kidney and cancer. CA Cancer J Clin. 2021 Jan;71(1):47-77. doi: 10.3322/caac.21636. Epub 2020 Aug 27. PMID: 32853404.
Adhikari S, Mamlouk O, Rondon-Berrios H, Workeneh BT. Hypophosphatemia in cancer patients. Clin Kidney J. 2021 Apr 15;14(11):2304-2315. doi: 10.1093/ckj/sfab078. PMID: 34754427; PMCID: PMC8572986.
Bozic B, Rutner J, Zheng C, Ruckser R, Selimi F, Racz K, Köcher M, Tatzreiter G, Sebesta C. Advances in the Treatment of Relapsed and Refractory Multiple Myeloma in Patients with Renal Insufficiency: Novel Agents, Immunotherapies and Beyond. Cancers (Basel). 2021 Oct 9;13(20):5036. doi: 10.3390/cancers13205036. PMID: 34680184; PMCID: PMC8533858.
Ratanasrimetha P, Workeneh BT, Seethapathy H. Sodium and Potassium Dysregulation in the Patient With Cancer. Adv Chronic Kidney Dis. 2022 Mar;29(2):171-179.e1. doi: 10.1053/j.ackd.2022.01.003. PMID: 35817524.
Zafar W, Kalra K, Ortiz-Melo DI. Oncosurgery-Related Acute Kidney Injury. Adv Chronic Kidney Dis. 2022 Mar;29(2):161-170.e1. doi: 10.1053/j.ackd.2022.04.001. PMID: 35817523.
Corona AG, Garcia P, Gelfand SL. Palliative Care for Patients With Cancer and Kidney Disease. Adv Chronic Kidney Dis. 2022 Mar;29(2):201-207.e1. doi: 10.1053/j.ackd.2021.11.007. PMID: 35817527.
Singh V, Khan N, Jayandharan GR. Vector engineering, strategies and targets in cancer gene therapy. Cancer Gene Ther. 2022 May;29(5):402-417. doi: 10.1038/s41417-021-00331-7. Epub 2021 Apr 15. PMID: 33859378.
Tonooka A, Ohashi R. Current Trends in Anti-Cancer Molecular Targeted Therapies: Renal Complications and Their Histological Features. J Nippon Med Sch. 2022 May 12;89(2):128-138. doi: 10.1272/jnms.JNMS.2022_89-221. Epub 2021 Nov 26. PMID: 34840210.
Bonilla M, Jhaveri KD, Izzedine H. Anaplastic lymphoma kinase inhibitors and their effect on the kidney. Clin Kidney J. 2022 Feb 26;15(8):1475-1482. doi: 10.1093/ckj/sfac062. PMID: 35892021; PMCID: PMC9308093.
Latcha S, Shah CV. Rescue Therapies for AKI in Onconephrology: Rasburicase and Glucarpidase. Semin Nephrol. 2022 Nov;42(6):151342. doi: 10.1016/j.semnephrol.2023.151342. Epub 2023 May 9. PMID: 37167817.
Blosser CD, Portuguese AJ, Santana C, Murakami N. Transplant Onconephrology: An Update. Semin Nephrol. 2022 Nov;42(6):151348. doi: 10.1016/j.semnephrol.2023.151348. Epub 2023 May 18. PMID: 37209580; PMCID: PMC10330527.
Shirali AC, Sprangers B. Cancer Drug Dosing in Chronic Kidney Disease and Dialysis. Adv Chronic Kidney Dis. 2022 Mar;29(2):208-216.e1. doi: 10.1053/j.ackd.2021.12.002. PMID: 35817528
Lupușoru G, Ailincăi I, Frățilă G, Ungureanu O, Andronesi A, Lupușoru M, Banu M, Văcăroiu I, Dina C, Sinescu I. Tumor Lysis Syndrome: An Endless Challenge in Onco-Nephrology. Biomedicines. 2022 Apr 28;10(5):1012. doi: 10.3390/biomedicines10051012. PMID: 35625753; PMCID: PMC9138780
Sandhu G, Adattini J, Armstrong Gordon E, O’Neill N. On behalf of the ADDIKD Guideline Working Group. International consensus guideline on anticancer drug dosing in kidney dysfunction. 2022. eviQ, Cancer Institute NSW. St Leonards, Australia
Uppal NN, Workeneh BT, Rondon-Berrios H, Jhaveri KD. Electrolyte and Acid- Base Disorders Associated with Cancer Immunotherapy. Clin J Am Soc Nephrol. 2022 Jun;17(6):922-933. doi: 10.2215/CJN.14671121. Epub 2022 Jan 21. PMID: 35063968; PMCID: PMC9269647.
Gupta S, Murakami N. Introduction: Clinical Innovations in Onconephrology: What's New in 2023. Semin Nephrol. 2022 Nov;42(6):151350. doi: 10.1016/j.semnephrol.2023.151350. Epub 2023 Apr 26. PMID: 37116349.
Casals J, Acosta Y, Caballero G, Morantes L, Zamora C, Xipell M, Viladot M, Guillen E, Piñeiro G, Blasco M, Marco J, Padrosa J, Pereira A, Jhaveri KD, Quintana LF, García-Herrera A. Differentiating Acute Interstitial Nephritis From Immune Checkpoint Inhibitors From Other Causes. Kidney Int Rep. 2022 Dec 29;8(3):672-675. doi: 10.1016/j.ekir.2022.12.017. PMID: 36938095; PMCID: PMC10014382
Bermejo S, Bolufer M, Riveiro-Barciela M, Soler MJ. Immunotherapy and the Spectrum of Kidney Disease: Should We Individualize the Treatment? Front Med (Lausanne). 2022 Jun 14;9:906565. doi: 10.3389/fmed.2022.906565. PMID: 35775000; PMCID: PMC9237407.
García-Carro C, Bolufer M, Bury R, Castañeda Z, Muñoz E, Felip E, Lorente D, Carreras MJ, Gabaldon A, Agraz I, Serón D, Soler MJ. Acute kidney injury as a risk factor for mortality in oncological patients receiving checkpoint inhibitors. Nephrol Dial Transplant. 2022 Apr 25;37(5):887-894. doi: 10.1093/ndt/gfab034. PMID: 33547795.
Bharati J, Lahoud OB, Jhaveri KD, Izzedine H. AA Amyloidosis associated with cancers. Nephrol Dial Transplant. 2022 Jul 22:gfac217. doi: 10.1093/ndt/gfac217. Epub ahead of print. PMID: 35867878.
Bolufer M, García-Carro C, Blasco M, Quintana LF, Shabaka A, Rabasco C, Draibe J, Merino A, Melero MR, Alonso F, Buxeda A, Batalha P, Visús MT, Soler MJ. Kidney Biopsy in Patients with Cancer along the Last Decade: A Multicenter Study. J Clin Med. 2022 May 21;11(10):2915. doi: 10.3390/jcm11102915. PMID: 35629041; PMCID: PMC9143132.
Gupta S, Gudsoorkar P, Jhaveri KD. Acute Kidney Injury in Critically Ill Patients with Cancer. Clin J Am Soc Nephrol. 2022 Mar 25;17(9):1385–98. doi: 10.2215/CJN.15681221. Epub ahead of print. PMID: 35338071; PMCID: PMC9625110.
Gudsoorkar P, Jhaveri KD, Sise ME. Onconephrology: The Growth of Cancer- Kidney Connection, Part 2. Adv Chronic Kidney Dis. 2022 Mar;29(2):83-85. doi: 10.1053/j.ackd.2022.05.001. PMID: 35817529.
Documento "Efectos renales adversos por Inhibidores del Check Point (ICP) en pacientes con cáncer. Recomendaciones del grupo Onconefrología de la S.E.N." (Ref. NEFRO-S-22-00526)
Mehmet Kanbay, Sidar Copur, Dimitrie Siriopol, Abdullah Burak Yildiz, Metehan Berkkan, Raluca Popa, Nuri Baris Hasbal, Alberto Ortiz, Mark A Perazella, The association between acute kidney injury and outcomes in cancer patients receiving immune checkpoint inhibitor therapy: a systematic review and meta-analysis, Clinical Kidney Journal, 2022, sfac194, https://doi.org/10.1093/ckj/sfac194
Rosner MH, Darmon M, Ostermann M. Onco-nephrology: what the intensivist needs to know. Intensive Care Med. 2022 Sep;48(9):1234-1236. doi: 10.1007/s00134-022-06840-9. Epub 2022 Aug 9. PMID: 35943571.
Gupta S, Garcia-Carro C, Prosek JM, Glezerman I, Herrmann SM, Garcia P, Abudayyeh A, Lumlertgul N, Malik AB, Loew S, Beckerman P, Renaghan AD, Carlos CA, Rashidi A, Mithani Z, Deshpande P, Rangarajan S, Shah CV, Seigneux S, Campedel L, Kitchlu A, Shin DS, Coppock G, Ortiz-Melo DI, Sprangers B, Aggarwal V, Benesova K, Wanchoo R, Murakami N, Cortazar FB, Reynolds KL, Sise ME, Soler MJ, Leaf DE; ICPi-AKI Consortium Investigators. Shorter versus longer corticosteroid duration and recurrent immune checkpoint inhibitor-associated AKI. J Immunother Cancer. 2022 Sep;10(9):e005646. doi: 10.1136/jitc-2022-005646. PMID: 36137651; PMCID: PMC9511654.
Kanduri SR, Kovvuru K, Wickman TJ, Velez JCQ. A case of tumor-induced osteomalacia masked by acute kidney injury. Journal of Onco-Nephrology. 2022;0(0). doi:10.1177/23993693221134954
Sprangers B, Leaf DE, Porta C, Soler MJ, Perazella MA. Diagnosis and management of immune checkpoint inhibitor-associated acute kidney injury. Nat Rev Nephrol. 2022 Dec;18(12):794-805. doi: 10.1038/s41581-022-00630-8. Epub 2022 Sep 27. PMID: 36168055.
Minº Sanidad. IPT TTº MIELOMA MÚLTIPLE 2022
Wood AC, Perez AP, Arciola B, Patel K, Johnson G, DiMaggio E, Bachmeier CA, Reid K, Carallo S, Vargas MH, Faramand R, Chavez JC, Shah B, Gaballa S, Khimani F, Elmariah H, Nishihori T, Lazaryan A, Freeman C, Davila ML, Locke FL, Mhaskar R, Bassil C, Jain MD. Outcomes of CD19-Targeted Chimeric Antigen Receptor T Cell Therapy for Patients with Reduced Renal Function Including Dialysis. Transplant Cell Ther. 2022 Dec;28(12):829.e1-829.e8. doi: 10.1016/j.jtct.2022.09.009. Epub 2022 Sep 26. PMID: 36174934; PMCID: PMC9791940.
Costa E Silva VT, Gil LA Jr, Inker LA, Caires RA, Costalonga E, Coura-Filho G, Sapienza MT, Castro G Jr, Estevez-Diz MD, Zanetta DMT, Antonângelo L, Marçal L, Tighiouart H, Miao S, Mathew P, Levey AS, Burdmann EA. A prospective cross- sectional study estimated glomerular filtration rate from creatinine and cystatin C in adults with solid tumors. Kidney Int. 2022 Mar;101(3):607-614. doi: 10.1016/j.kint.2021.12.010. Epub 2022 Jan 12. PMID: 35032521.
Motwani SS, Kaur SS, Kitchlu A. Cisplatin Nephrotoxicity: Novel Insights Into Mechanisms and Preventative Strategies. Semin Nephrol. 2022 Nov;42(6):151341. doi: 10.1016/j.semnephrol.2023.151341. Epub 2023 May 12. PMID: 37182407.
Bonilla M, Jhaveri KD, Izzedine H. Anaplastic lymphoma kinase inhibitors and their effect on the kidney. Clin Kidney J. 2022 Feb 26;15(8):1475-1482. doi: 10.1093/ckj/sfac062. PMID: 35892021; PMCID: PMC9308093.
Bonilla M, Gudsoorkar P, Wanchoo R, Herrmann SM, Jhaveri KD. Onconephrology 2022: An Update. Kidney360. 2023 Feb 1;4(2):258-271. doi: 10.34067/KID.0001582022. Epub 2022 Dec 9. PMID: 36821617; PMCID: PMC10103386.
Rashidi A, Wanchoo R, Izzedine H. How I Manage Hypertension and Proteinuria Associated with VEGF Inhibitor. Clin J Am Soc Nephrol. 2023 Jan 1;18(1):121-123. doi: 10.2215/CJN.05610522. Epub 2022 Aug 17. PMID: 35977777; PMCID: PMC10101584.
Chowdhury R, Turcotte AE, Rondon-Berrios H, Workeneh BT. Spurious Electrolyte and Acid-Base Disorders in the Patient With Cancer: A Review. Am J Kidney Dis. 2023 Mar 9:S0272-6386(23)00560-7. doi: 10.1053/j.ajkd.2023.01.441. Epub ahead of print. PMID: 36906215.
García-Carro C, Draibe J, Soler MJ. Onconephrology: Update in Anticancer Drug-Related Nephrotoxicity. Nephron. 2023;147(2):65-77. doi: 10.1159/000525029. Epub 2022 Jun 17. PMID: 35717937.
Guven DC, Ozbek DA, Sahin TK, Kavgaci G, Aksun MS, Erul E, Yildirim HC, Chalabiyev E, Cebroyilov C, Yildirim T, Dizdar O, Aksoy S, Yalcin S, Kilickap S, Erman M, Arici M. The incidence and risk factors for acute kidney injury in patients treated with immune checkpoint inhibitors. Anticancer Drugs. 2023 Jul 1;34(6):783-790. doi: 10.1097/CAD.0000000000001463. Epub 2022 Dec 19. PMID: 36729111.
Saillant A, Try M, Laparra A, Lecoq AL, Zaidan M. Principaux troubles hydro- électrolytiques chez le patient de cancérologie [Electrolyte disorders in oncological patients]. Bull Cancer. 2023 May 17:S0007-4551(23)00209-6. French. doi: 10.1016/j.bulcan.2023.04.014. Epub ahead of print. PMID: 37208250.
García P. J Onconephrol 2023. Kidney function while on immune checkpoint inhibitors: Trends in incidence of acute kidney injury, and its causes and outcomes
J Onconephrol 2023 KWAK. A brief review of renal-limited thrombotic microangiopathy associated with immune checkpoint inhibitors.
Florio G, Iervolino A, Simeoni M, Perna AF, Trepiccione F. [Hyponatremia and Electrolyte Disorders in Cancer Patients]. G Ital Nefrol. 2023 Oct 3;40(Suppl 81):2023-S81. Italian. PMID: 38007830.
Caza TN, Jhaveri KD. Glomerular diseases post-hematopoietic stem cell transplantation: pathologic spectrum and plausible mechanisms. Clin Kidney J. 2023 Feb 6;16(6):896-900. doi: 10.1093/ckj/sfad023. PMID: 37261003; PMCID: PMC10229267.
Klomjit N, Evans R, Le TK, Wells SL, Ortega J, Green-Lingren O, Mazepa M, Sise ME, Jhaveri KD, Gupta S. Frequency and characteristics of chemotherapy- associated thrombotic microangiopathy: Analysis from a large pharmacovigilance database. Am J Hematol. 2023 Dec;98(12):E369-E372. doi: 10.1002/ajh.27101. Epub 2023 Sep 23. PMID: 37740927; PMCID: PMC10844958.
Yarandi N, Shirali AC. Onco-Nephrology: Kidney Disease in the Cancer Patient. Med Clin North Am. 2023 Jul;107(4):749-762. doi: 10.1016/j.mcna.2023.03.007. Epub 2023 Apr 19. PMID: 37258012.
Trisal SR, Low G, Pathan F, Gangadharan Komala M. Kidney Adverse Events Associated with Immune Checkpoint Inhibitor Therapy: A Systematic Review and Bayesian Network Meta-Analysis. Clin J Am Soc Nephrol. 2023 Mar 31;18(7):843–9. doi: 10.2215/CJN.0000000000000160. Epub ahead of print. PMID: 36999976; PMCID: PMC10356161.
Hatakeyama Y, Horino T, Yasui S, Komori M, Terada Y, Okuhara Y. Incidence of acute kidney injury and decreased estimated glomerular filtration rate according to the site of cancer. Clin Exp Nephrol. 2023 Mar;27(3):262-271. doi: 10.1007/s10157-022-02303-z. Epub 2022 Dec 27. PMID: 36574103.
Siddiq S, Hussain Z, Mubarakali J, Nazir A. Incidence, Patterns, and Characteristics of Patients With Acute Kidney Injury Requiring Renal Replacement Therapy in Cancer Settings. Cureus. 2023 Nov 10;15(11):e48627. doi: 10.7759/cureus.48627. PMID: 38084195; PMCID: PMC10710874.
Hanna PE, Wang Q, Strohbehn I, Moreno D, Harden D, Ouyang T, Katz-Agranov N, Seethapathy H, Reynolds KL, Gupta S, Leaf DE, Sise ME. Medication-related adverse events in patients with cancer and discrepancies in cystatin C- versus creatinine-based eGFR. medRxiv [Preprint]. 2023 Jan 18:2023.01.18.23284656. doi: 10.1101/2023.01.18.23284656. PMID: 36711583; PMCID: PMC9882433.
Alonso F, Martín de Francisco ÁLM, Auñón P, García-Carro C, García P, Gutiérrez E, Mcía M, Quintana LF, Quiroga B, Soler MJ, Torregrosa I; Onconephrology Group of the Spanish Society of Nephrology. Adverse renal effects of check-point inhibitors (ICI) in cancer patients: Recommendations of the Onco- nephrology Working Group of the Spanish Society of Nephrology. Nefrologia (Engl Ed). 2023 Sep-Oct;43(5):622-635. doi: 10.1016/j.nefroe.2023.11.001. Epub 2023 Nov 23. PMID: 38000944.
Habas E, Akbar R, Farfar K, Arrayes N, Habas A, Rayani A, Alfitori G, Habas E, Magassabi Y, Ghazouani H, Aladab A, Elzouki AN. Malignancy diseases and kidneys: A nephrologist prospect and updated review. Medicine (Baltimore). 2023 Apr 14;102(15):e33505. doi: 10.1097/MD.0000000000033505. PMID: 37058030; PMCID: PMC10101313.
Kitchlu A, Chan CT, Jhaveri KD, Delgado D, Tam P. Amyloidoses in Onco- Nephrology Practice: A Multidisciplinary Case-Based Conference Report. Can J Kidney Health Dis. 2023 Apr 18;10:20543581231165711. doi: 10.1177/20543581231165711. PMID: 37101848; PMCID: PMC10123889.
Bonilla M, Workeneh BT, Uppal NN. Hypomagnesemia in Patients With Cancer: The Forgotten Ion. Semin Nephrol. 2022 Nov;42(6):151347. doi: 10.1016/j.semnephrol.2023.151347. Epub 2023 Apr 21. PMID: 37086496
Pandey S, Kalaria A, Jhaveri KD, Herrmann SM, Kim AS. Management of hypertension in patients with cancer: challenges and considerations. Clin Kidney J. 2023 Aug 12;16(12):2336-2348. doi: 10.1093/ckj/sfad195. PMID: 38046043; PMCID: PMC10689173.
Yarandi N, Shirali AC. Onconephrology: Core Curriculum 2023. Am J Kidney Dis. 2023 Dec;82(6):743-761. doi: 10.1053/j.ajkd.2023.04.014. Epub 2023 Oct 17. PMID: 37855786.
Matsubara T, Yokoi H, Yamada H, Yanagita M. Nephrotoxicity associated with anticancer agents: perspective on onconephrology from nephrologists. Int J Clin Oncol. 2023 May;28(5):625-636. doi: 10.1007/s10147-023-02307-z. Epub 2023 Mar 5. PMID: 36872414.
Terashita M, Selamet U, Midha S, Nadeem O, Laubach J, Rennke HG, Murakami N. Clinical Outcomes of Monoclonal Gammopathy of Renal Significance Without Detectable Clones. Kidney Int Rep. 2023 Sep 22;8(12):2765-2777. doi: 10.1016/j.ekir.2023.09.022. PMID: 38106576; PMCID: PMC10719651.
Wu HHL, Chinnadurai R, Walker RJ, Tennankore KK. Is It Time to Integrate Frailty Assessment in Onconephrology? Cancers (Basel). 2023 Mar 8;15(6):1674. doi: 10.3390/cancers15061674. PMID: 36980558; PMCID: PMC10046649.
Vanhoutte T, Sprangers B. Pseudo-AKI associated with targeted anti-cancer agents-the truth is in the eye of the filtration marker. Clin Kidney J. 2023 Jan 16;16(4):603-610. doi: 10.1093/ckj/sfad011. PMID: 37007700; PMCID: PMC10061433.
Geraldes C, Roque A, Sarmento-Ribeiro AB, Neves M, Ionita A, Gerivaz R, Tomé A, Afonso S, Silveira MP, Sousa P, Bergantim R, João C. Practical management of disease-related manifestations and drug toxicities in patients with multiple myeloma. Front Oncol. 2024 Mar 22;14:1282300. doi: 10.3389/fonc.2024.1282300. PMID: 38585008; PMCID: PMC10995327
Karam S, Rosner MH, Sprangers B, Stec R, Malyszko J. Cancer therapy in patients with reduced kidney function. Nephrol Dial Transplant. 2024 Jun 24:gfae142. doi: 10.1093/ndt/gfae142. Epub ahead of print. PMID: 38914465.
Kitchlu A, Assessment of Glomerular Filtration Rate in Patients with Cancer: A Statement from the American Society of Onco- Nephrology. Clin J Am Soc Nephrol. 2024 Jun 7. doi: 10.2215
Chen JJ, Lee TH, Kuo G, Yen CL, Lee CC, Chang CH, Tu KH, Chen YC, Fang JT, Hung CC, Yang CW, Chou WC, Chi CC, Tu YK, Yu Yang H. All-cause and immune checkpoint inhibitor-associated acute kidney injury in immune checkpoint inhibitor users: a meta-analysis of occurrence rate, risk factors and mortality. Clin Kidney J. 2023 Nov 28;17(1):sfad292. doi: 10.1093/ckj/sfad292. PMID: 38186874; PMCID: PMC10768773
García-Carro C, Jhaveri KD, Sprangers B. Revisiting the role of acute kidney injury in patients on immune checkpoint inhibitors: a good prognosis renal event with a significant impact on survival. Clin Kidney J. 2023 Feb 28;16(5):773-775. doi: 10.1093/ckj/sfad035. PMID: 37151419; PMCID: PMC10157754.
Attieh RM, Begum F, Chitty D, Izzedine H, Jhaveri KD. Kidney and Urinary Tract Involvement in Chronic Myelomonocytic Leukemia. Kidney Med. 2023 Dec 5;6(2):100769. doi: 10.1016/j.xkme.2023.100769. PMID: 38313809; PMCID: PMC10837097.
Li Y, Ju M, Miao Y, Zhao L, Xing L, Wei M. Advancement of anti-LAG-3 in cancer therapy. FASEB J. 2023 Nov;37(11):e23236. doi: 10.1096/fj.202301018R. PMID: 37846808.
León-Román J, Iacoboni G, Bermejo S, Carpio C, Bolufer M, García-Carro C, Sánchez-Salinas M, Alonso-Martínez C, Bestard O, Barba P, Soler MJ. Transient acute kidney injury after chimeric antigen receptor T-cell therapy in patients with hematological malignancies. Clin Kidney J. 2024 Feb 20;17(3):sfae027. doi: 10.1093/ckj/sfae027. PMID: 38500492; PMCID: PMC10946657.
Ibrahim R, Saleh K, Chahine C, Khoury R, Khalife N, Cesne AL. LAG-3 Inhibitors: Novel Immune Checkpoint Inhibitors Changing the Landscape of Immunotherapy. Biomedicines. 2023 Jul 1;11(7):1878. doi: 10.3390/biomedicines11071878. PMID: 37509517; PMCID: PMC10377063.
León-Román J, Iacoboni G, Bermejo S, Carpio C, Bolufer M, García-Carro C, Sánchez-Salinas M, Alonso-Martínez C, Bestard O, Barba P, Soler MJ. Transient acute kidney injury after chimeric antigen receptor T-cell therapy in patients with hematological Aggarwal V, Workman CJ, Vignali DAA. LAG-3 as the third checkpoint i
Gallan AJ, Bhasin-Chhabra B, Kilari D, Johnson S, D'Souza A. Bystander LECT2 amyloidosis in tumor nephrectomy. CEN Case Rep. 2023 Feb;12(1):104-109. doi: 10.1007/s13730-022-00728-9. Epub 2022 Aug 20. PMID: 35986199; PMCID: PMC9892383.
Hafez MH. Onconephrology and Transplant Oncology. Exp Clin Transplant. 2024 Jan;22(Suppl 1):56-59. doi: 10.6002/ect.MESOT2023.L44. PMID: 38385373.
Bonilla M, Geara AS. Onconephrology Fellowship Training: Current Status and Future Outlook. Kidney360. 2024 Sep 1;5(9):1380-1385. doi: 10.34067/KID.0000000000000495. PMID: 39325593; PMCID: PMC11441803.
Selamet U, Ahdoot RS, Salasnek R, Abdelnour L, Hanna RM. Onconephrology: mitigation of renal injury in chemotherapy administration. Curr Opin Nephrol Hypertens. 2024 Mar 1;33(2):257-266. doi: 10.1097/MNH.0000000000000960. Epub 2023 Dec 14. PMID: 38095483
Murakami N, Wong G. Introduction: Clinical Innovations in Transplant Onconephrology. Semin Nephrol. 2024 Jan;44(1):151493. doi: 10.1016/j.semnephrol.2024.151493. Epub 2024 Mar 11. PMID: 38472079.
Hanna PE, Chowdhury R, Solhjou Z, Gupta S, Jhaveri KD. Challenges for optimal care in onconephrology. Nephrol Dial Transplant. 2024 Jan 31;39(2):167-169. doi: 10.1093/ndt/gfad160. PMID: 37442629; PMCID: PMC10828197.
Pirovano M, Ganini C, Gallieni M, Porta C, Cosmai L. Management of cytotoxic chemotherapy in patients undergoing dialysis: a still unresolved issue of onconephrology. J Nephrol. 2024 Oct 15. doi: 10.1007/s40620-024-02102-7. Epub ahead of print. PMID: 39404957
Muthukumaran A, Wanchoo R, Seshan SV, Gudsoorkar P. Paraneoplastic Glomerular Diseases. Adv Kidney Dis Health. 2024 Jul;31(4):346-357. doi: 10.1053/j.akdh.2024.04.008. PMID: 39084760.
Gupta S, Glezerman IG, Hirsch JS, Chen KL, Devaraj N, Wells SL, Seitter RH, Kaunfer SA, Jose AM, Rao SP, Ortega JL, Green-Lingren O, Hayden R, Bendapudi PK, Chute DF, Sise ME, Jhaveri KD, Page VD, Abramson MH, Motwani SS, Xu W, Sehgal K, Reynolds KL, Bansal A, Abudayyeh A, Leaf DE. Derivation and external validation of a simple risk score for predicting severe acute kidney injury after intravenous cisplatin: cohort study. BMJ. 2024 Mar 27;384:e077169. doi: 10.1136/bmj-2023-077169. Erratum in: BMJ. 2024 Jun 20;385:q1207. doi: 10.1136/bmj.q1207. PMID: 38538012; PMCID: PMC10964715.
Chowdhury R, Gupta S. Monoclonal Gammopathies and CKD Progression: An Unfinished Story. Clin J Am Soc Nephrol. 2024 Mar 1;19(3):280-282. doi: 10.2215/CJN.0000000000000401. Epub 2024 Jan 3. PMID: 38170512; PMCID: PMC10937021.
Gueutin V, Cardineau A, Mathian A, Lanot A, Comoz F, Brocheriou I, Izzedine H. Renal involvement in solid cancers: epidemiological, clinical and histological characteristics study of 154 onconephrology patients. BMC Nephrol. 2024 Oct 19;25(1):367. doi: 10.1186/s12882-024-03812-7. PMID: 39427142; PMCID: PMC11490999.
Parodi E, Rossi M, Bottiglieri A, Ladetto M, Merlotti G, Cantaluppi V, Quaglia M. Pharmacotherapy considerations in patients who develop acute kidney injury during anti-cancer therapy. Expert Opin Pharmacother. 2024 Apr;25(5):595-610. doi: 10.1080/14656566.2024.2346268. Epub 2024 Apr 25. PMID: 38646905.
Kitchlu A, Silva VTCE, Anand S, Kala J, Abudayyeh A, Inker LA, Rosner MH, Karam S, Gudsoorkar P, Gupta S, Chen S, Klomjit N, Leung N, Milanez T, Motwani SS, Khalid SB, Srinivasan V, Wanchoo R, Beumer JH, Liu G, Tannir NM, Orchanian- Cheff A, Geng Y, Herrmann SM. Assessment of GFR in Patients with Cancer: A Statement from the American Society of Onco-Nephrology. Clin J Am Soc Nephrol. 2024 Aug 1;19(8):1061-1072. doi: 10.2215/CJN.0000000000000508. Epub 2024 Jun 7. PMID: 38848131; PMCID: PMC11321742.
Kitchlu A, Silva VTCE, Anand S, Kala J, Abudayyeh A, Inker LA, Rosner MH, Karam S, Gudsoorkar P, Gupta S, Chen S, Klomjit N, Leung N, Milanez T, Motwani SS, Khalid SB, Srinivasan V, Wanchoo R, Beumer JH, Liu G, Tannir NM, Orchanian- Cheff A, Geng Y, Herrmann SM. Assessment of GFR in Patients with Cancer Part 2: Anticancer Therapies-Perspectives from the American Society of Onco-Nephrology (ASON). Clin J Am Soc Nephrol. 2024 Aug 1;19(8):1073-1077. doi: 10.2215/CJN.0000000000000509. Epub 2024 Jun 7. PMID: 39316409; PMCID: PMC11321741.
Brown RB, Bigelow P, Dubin JA, Neiterman E. Breast cancer, alcohol, and phosphate toxicity. J Appl Toxicol. 2024 Jan;44(1):17-27. doi: 10.1002/jat.4504. Epub 2023 Jun 18. PMID: 37332052.
Karam S, Rosner MH, Sprangers B, Stec R, Malyszko J. Cancer therapy in patients with reduced kidney function. Nephrol Dial Transplant. 2024 Nov 27;39(12):1976-1984. doi: 10.1093/ndt/gfae142. PMID: 38914465.
Lyrio RMDC, Rocha BRA, Corrêa ALRM, Mascarenhas MGS, Santos FL, Maia RDH, Segundo LB, de Almeida PAA, Moreira CMO, Sassi RH. Chemotherapy-induced acute kidney injury: epidemiology, pathophysiology, and therapeutic approaches. Front Nephrol. 2024 Aug 9;4:1436896. doi: 10.3389/fneph.2024.1436896. PMID: 39185276; PMCID: PMC11341478
Attieh RM, Nunez B, Copeland-Halperin RS, Jhaveri KD. Cardiorenal Impact of Anti-Cancer Agents: The Intersection of Onco-Nephrology and Cardio-Oncology. Cardiorenal Med. 2024;14(1):281-293. doi: 10.1159/000539075. Epub 2024 Apr 29. PMID: 38684145.
Alamilla-Sanchez M, Diaz Garcia JD, Yanez Salguero V, Morales Lopez F, Ulloa Galvan V, Velasco Garcia-Lascurain F, Yama Estrella B. Chemotherapy-induced tubulopathy: a case report series. Front Nephrol. 2024 Apr 11;4:1384208. doi: 10.3389/fneph.2024.1384208. PMID: 38666245; PMCID: PMC11043590.
Cheema PK, Iafolla MAJ, Abdel-Qadir H, Bellini AB, Chatur N, Chandok N, Comondore VR, Cunningham M, Halperin I, Hu AB, Jaskolka D, Darvish-Kazem S, Khandaker MH, Kitchlu A, Sachdeva JS, Shapera S, Woolnough NRJ, Nematollahi M. Managing Select Immune-Related Adverse Events in Patients Treated with Immune Checkpoint Inhibitors. Curr Oncol. 2024 Oct 18;31(10):6356-6383. doi: 10.3390/curroncol31100473. PMID: 39451777; PMCID: PMC11506662.
Porta C, Negri F, Cosmai L. Hepatocellular carcinoma, vascular endothelial growth factor receptors-targeting agents, and hypertension: A much more complicated relationship than expected. Cancer. 2024 Apr 15;130(8):1208-1209. doi: 10.1002/cncr.35218. Epub 2024 Jan 27. PMID: 38280211.
Hanna PE, Ouyang T, Tahir I, Katz-Agranov N, Wang Q, Mantz L, Strohbehn I, Moreno D, Harden D, Dinulos JE, Cosar D, Seethapathy H, Gainor JF, Shah SJ, Gupta S, Leaf DE, Fintelmann FJ, Sise ME. Sarcopenia, adiposity and large discordance between cystatin C and creatinine-based estimated glomerular filtration rate in patients with cancer. J Cachexia Sarcopenia Muscle. 2024 Jun;15(3):1187-1198. doi: 10.1002/jcsm.13469. Epub 2024 Apr 22. PMID: 38646842; PMCID: PMC11154767.
Floris M, Trevisani F, Angioi A, Lepori N, Simeoni M, Cabiddu G, Pani A, Rosner MH. Acute Kidney Disease in Oncology: A New Concept to Enhance the Understanding of the Impact of Kidney Injury in Patients with Cancer. Kidney Blood Press Res. 2024;49(1):745-752. doi: 10.1159/000540908. Epub 2024 Aug 19. PMID: 39159615.
Kala J, Joseph T, Pirovano M, Fenoglio R, Cosmai L. Acute Kidney Injury Associated with Anticancer Therapies: Small Molecules and Targeted Therapies. Kidney360. 2024 Nov 1;5(11):1750-1762. doi: 10.34067/KID.0000000566. Epub 2024 Aug 26. PMID: 39186376.
Gueutin V, Dalle S, Isnard-Bagnis C, Laparra A, Assad S, Burtey S, Audard V, Belliere J. Insuffisance rénale aiguë chez les patients traités par inhibiteur du check-point immunitaire-recommandations communes FITC/SFNDT [Acute kidney injury in cancer patients receiving immune checkpoint inhibitor therapy-shared guidelines of FITC/SFNDT]. Bull Cancer. 2024 Dec 5:S0007-4551(24)00453-3. French. doi: 10.1016/j.bulcan.2024.11.001. Epub ahead of print. PMID: 39643454.
Mancianti N, Tripodi SA, Pascucci A, Calatroni M, La Porta E, Guarnieri A, Garosi G. Immunohistochemical Evaluation of Renal Biopsy with Anti-PD1 and p53 to Solve the Dilemma between Platinum- and Pembrolizumab-Induced AKI: Case Report and Review. J Clin Med. 2024 Mar 22;13(7):1828. doi: 10.3390/jcm13071828. PMID: 38610593; PMCID: PMC11012688.
Kanbay M, Mizrak B, Alper EN, Copur S, Ortiz A. Acute kidney injury following CAR-T cell therapy: a nephrologist's perspective. Clin Kidney J. 2024 Nov 15;18(1):sfae359. doi: 10.1093/ckj/sfae359. PMID: 39781479; PMCID: PMC11704793.
Hammouri D, Orwick A, Doll MA, Sanchez Vega D, Shah PP, Clarke CJ, Clem B, Beverly LJ, Siskind LJ. Remote organ cancer induces kidney injury, inflammation, and fibrosis and adversely alters renal function. Am J Physiol Renal Physiol. 2024 Dec 16. Epub ahead of print. PMID: 39681358.
Ector C, Schmal C, Didier J, De Landtsheer S, Finger AM, Müller-Marquardt F, Schulte JH, Sauter T, Keilholz U, Herzel H, Kramer A, Granada AE. Time-of-day effects of cancer drugs revealed by high-throughput deep phenotyping. Nat Commun. 2024 Aug 22;15(1):7205. doi: 10.1038/s41467-024-51611-3. PMID: 39169017; PMCID: PMC11339390.
Katsikis PD, Ishii KJ, Schliehe C. Challenges in developing personalized neoantigen cancer vaccines. Nat Rev Immunol. 2024 Mar;24(3):213-227. doi: 10.1038/s41577-023-00937-y. Epub 2023 Oct 2. PMID: 37783860.
Chi WY, Hu Y, Huang HC, Kuo HH, Lin SH, Kuo CJ, Tao J, Fan D, Huang YM, Wu AA, Hung CF, Wu TC. Molecular targets and strategies in the development of nucleic acid cancer vaccines: from shared to personalized antigens. J Biomed Sci. 2024 Oct 9;31(1):94. doi: 10.1186/s12929-024-01082-x. PMID: 39379923; PMCID: PMC11463125.
Zeng W, Wang M, Zhang Y, Zhou T, Zong Z. Targeting mitochondrial damage: shining a new light on immunotherapy. Front Immunol. 2024 Jul 22;15:1432633. doi: 10.3389/fimmu.2024.1432633. Erratum in: Front Immunol. 2025 Mar 20;16:1591209. doi: 10.3389/fimmu.2025.1591209. PMID: 39104526; PMCID: PMC11298799.
Gork I, Xiong F, Kitchlu A. Cancer drugs and acute kidney injury: new therapies and new challenges. Curr Opin Nephrol Hypertens. 2024 Sep 1;33(5):474-485. doi: 10.1097/MNH.0000000000001001. Epub 2024 May 7. PMID: 38712677.
Rangaswamy D, Nagaraju SP, Bhojaraja MV, Swaminathan SM, Prabhu RA, Rao IR, Shenoy SV. Ocular and systemic vascular endothelial growth factor ligand inhibitor use and nephrotoxicity: an update. Int Urol Nephrol. 2024 Aug;56(8):2635-2644. doi: 10.1007/s11255-024-03990-1. Epub 2024 Mar 18. PMID: 38498275; PMCID: PMC11266217.
Herrmann SM, Abudayyeh A, Gupta S, Gudsoorkar P, Klomjit N, Motwani SS, Karam S, Costa E Silva VT, Khalid SB, Anand S, Kala J, Leaf DE, Murakami N, Rashidi A, Wanchoo R, Kitchlu A. Diagnosis and management of immune checkpoint inhibitor- associated nephrotoxicity: a position statement from the American Society of Onco-nephrology. Kidney Int. 2025 Jan;107(1):21-32. doi: 10.1016/j.kint.2024.09.017. Epub 2024 Oct 24. PMID: 39455026.
Braun DA, Moranzoni G, Chea V, McGregor BA, Blass E, Tu CR, Vanasse AP, Forman C, Forman J, Afeyan AB, Schindler NR, Liu Y, Li S, Southard J, Chang SL, Hirsch MS, LeBoeuf NR, Olive O, Mehndiratta A, Greenslade H, Shetty K, Klaeger S, Sarkizova S, Pedersen CB, Mossanen M, Carulli I, Tarren A, Duke-Cohan J, Howard AA, Iorgulescu JB, Shim B, Simon JM, Signoretti S, Aster JC, Elagina L, Carr SA, Leshchiner I, Getz G, Gabriel S, Hacohen N, Olsen LR, Oliveira G, Neuberg DS, Livak KJ, Shukla SA, Fritsch EF, Wu CJ, Keskin DB, Ott PA, Choueiri TK. A neoantigen vaccine generates antitumour immunity in renal cell carcinoma. Nature. 2025 Feb 5. doi: 10.1038/s41586-024-08507-5. Epub ahead of print. PMID: 39910301.
Li Q, Lin J, Hao G, Xie A, Liu S, Tang B. Nephrotoxicity of targeted therapy used to treat lung cancer. Front Immunol. 2024 Jul 4;15:1369118. doi: 10.3389/fimmu.2024.1369118. PMID: 39026680; PMCID: PMC11254629.
Díaz-Gay M, Zhang T, Hoang PH, Leduc C, Baine MK, Travis WD, Sholl LM, Joubert P, Khandekar A, Zhao W, Steele CD, Otlu B, Nandi SP, Vangara R, Bergstrom EN, Kazachkova M, Pich O, Swanton C, Hsiung CA, Chang IS, Wong MP, Leung KC, Sang J, McElderry JP, Hartman C, Colón-Matos FJ, Miraftab M, Saha M, Lee OW, Jones KM, Gallego-García P, Yang Y, Zhong X, Edell ES, Santamaría JM, Schabath MB, Yendamuri SS, Manczuk M, Lissowska J, Świątkowska B, Mukeria A, Shangina O, Zaridze D, Holcatova I, Mates D, Milosavljevic S, Kontic M, Bossé Y, Rothberg BEG, Christiani DC, Gaborieau V, Brennan P, Liu G, Hofman P, Yang L, Nowak MA, Shi J, Rothman N, Wedge DC, Homer R, Yang SR, Pesatori AC, Consonni D, Lan Q, Zhu B, Chanock SJ, Choi J, Alexandrov LB, Landi MT. The mutagenic forces shaping the genomes of lung cancer in never smokers. Nature. 2025 Jul 2. doi: 10.1038/s41586-025-09219-0. Epub ahead of print. PMID: 40604281.
Barbir EB, Leung N, Herrmann SM. Ten tips for an onco-nephrology clinic. Clin Kidney J. 2025 May 29;18(6):sfaf174. doi: 10.1093/ckj/sfaf174. PMID: 40589793; PMCID: PMC12207213.